E. Klyuchnikov

发表

Donor KIR haplotype B improves progression-free and overall survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma

N. Kröger, A. Zander, T. Binder, 2011, Leukemia.

Post-transplant immune reconstitution after unrelated allogeneic stem cell transplant in patients with acute myeloid leukemia

N. Kröger, A. Zander, W. Kern, 2010, Leukemia & lymphoma.

Donor lymphocyte infusions and second transplantation as salvage treatment for relapsed myelofibrosis after reduced‐intensity allografting

N. Kröger, A. Zander, A. Nagler, 2012, British journal of haematology.

Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?

J. Vose, Sonali M. Smith, P. Hari, 2012, Blood.

The Role of Allogeneic Stem Cell Transplantation in Relapsed/Refractory Hodgkin's Lymphoma Patients

N. Kröger, A. Zander, U. Bacher, 2010, Advances in hematology.

lymphoma: myeloablative or reduced intensity? Conditioning regimens for allotransplants for diffuse large B-cell

Sonali M. Smith, P. Hari, P. Armand, 2012 .

Current status and perspectives of tyrosine kinase inhibitor treatment in the posttransplant period in patients with chronic myelogenous leukemia (CML).

N. Kröger, A. Zander, U. Bacher, 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplantation in patients with multiple myeloma.

N. Kröger, D. Atanackovic, A. Zander, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Allogeneic hematopoietic cell transplantation for diffuse large B cell lymphoma: who, when and how?

T. Kroll, T. Shea, H. Lazarus, 2014, Bone Marrow Transplantation.

JAK2-V617F-triggered preemptive and salvage adoptive immunotherapy with donor-lymphocyte infusion in patients with myelofibrosis after allogeneic stem cell transplantation.

Y. Hildebrandt, N. Kröger, A. Zander, 2009, Blood.

Characterisation of extramedullary relapse in patients with chronic myeloid leukemia in advanced disease after allogeneic stem cell transplantation

T. Brümmendorf, N. Kröger, A. Zander, 2009, Leukemia & lymphoma.

Long-term survival outcomes of reduced-intensity allogeneic or autologous transplantation in relapsed grade 3 follicular lymphoma

Sonali M. Smith, N. Kröger, P. Hari, 2015, Bone Marrow Transplantation.

Chimerism studies with quantitative real-time PCR in stem cell recipients with acute myeloid leukemia.

C. Bokemeyer, T. Stahl, N. Kröger, 2010, Experimental hematology.

Post-transplant day +100 MRD detection rather than mixed chimerism predicts relapses after allo-SCT for intermediate risk AML patients transplanted in CR.

F. Ayuk, C. Wolschke, R. Massoud, 2022, Transplantation and cellular therapy.

Role of pre‐transplant MRD level detected by flow cytometry in recipients of allogeneic stem cell transplantation with AML

N. Kröger, C. Wolschke, U. Bacher, 2020, European journal of haematology.

Purification of CD4+ T cells for adoptive immunotherapy after allogeneic hematopoietic stem cell transplantation.

N. Kröger, A. Zander, B. Fehse, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Purification of CD 4 1 T Cells for Adoptive Immunotherapy after Allogeneic Hematopoietic Stem Cell Transplantation

N. Kröger, A. Zander, B. Fehse, 2011 .

Safety of conditioning agents for allogeneic haematopoietic transplantation

A. Zander, U. Bacher, E. Klyuchnikov, 2009, Expert opinion on drug safety.

The changing scene of allogeneic stem cell transplantation for chronic myeloid leukemia—a report from the German Registry covering the period from 1998 to 2004

N. Kröger, A. Zander, G. Ehninger, 2009, Annals of Hematology.

Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors.

Alan M. Miller, Sonali M. Smith, R. Vij, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Reduced-intensity allografting as first transplantation approach in relapsed/refractory grade 1-2 follicular lymphoma provides improved outcomes in long-term survivors Biol Blood Marrow Transplant

Alan M. Miller, Sonali M. Smith, R. Vij, 2015 .

Allogeneic stem cell transplantation in acute leukemia patients after COVID-19 infection

N. Kröger, C. Wolschke, F. Ayuk, 2021, Bone Marrow Transplantation.

Myeloablative and Reduced-intensity conditioned Allogeneic Haematopoietic Stem Cell Transplantation in Myelofibrosis: A Retrospective Study by the Chronic Malignancies Working Party of EBMT.

N. Kröger, L. Kanz, M. Robin, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Impact of Anti-T-lymphocyte globulin dosing on GVHD and Immune reconstitution in matched unrelated myeloablative peripheral blood stem cell transplantation

F. Ayuk, C. Wolschke, N. Gagelmann, 2022, Bone Marrow Transplantation.

Minimal residual disease diagnostics in patients with acute myeloid leukemia in the post-transplant period: comparison of peripheral blood and bone marrow analysis

T. Stahl, N. Kröger, A. Zander, 2010, Leukemia & lymphoma.

Post-transplant MFC-MRD status on day +100 predicts outcomes for refractory AML patients.

N. Kröger, F. Ayuk, C. Wolschke, 2022, Transplantation and cellular therapy.

Enhanced Immune Reconstitution of gd T Cells after Allogeneic Stem Cell Transplantation Overcomes the Negative Impact of Pretransplantation Minimal Residual Disease-Positive Status in Patients with Acute Myelogenous Leukemia Transplantation and Cellular Therapy

F. Ayuk, C. Wolschke, R. Massoud, 2021 .

Digital-droplet PCR assays for IDH, DNMT3A and driver mutations to monitor after allogeneic stem cell transplantation minimal residual disease of myelofibrosis

N. Kröger, B. Fehse, C. Wolschke, 2022, Bone Marrow Transplantation.

Treosulfan-Based Conditioning Regimen for Second Allograft in Patients with Myelofibrosis

N. Kröger, C. Wolschke, F. Ayuk, 2020, Cancers.

Post-transplant immunotherapy with donor-lymphocyte infusion and novel agents to upgrade partial into complete and molecular remission in allografted patients with multiple myeloma.

N. Kröger, D. Atanackovic, A. Zander, 2009, Experimental hematology.

Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory/relapsed myeloma patients

Y. Hildebrandt, N. Kröger, K. Pflüger, 2013, Bone Marrow Transplantation.

Outcome of patients with Myelofibrosis relapsing after allogeneic stem cell transplant: a retrospective study by the Chronic Malignancies Working Party of EBMT

N. Kröger, M. Robin, I. Yakoub-Agha, 2015, British journal of haematology.

Donor Lymphocyte Infusions and Second Transplantation as Salvage Treatment for Relapsed Myelofibrosis After Reduced-Intensity allografting.

N. Kröger, A. Zander, A. Nagler, 2010 .

Individualized busulfan dosing improves outcomes compared to fixed‐dose administration in pre‐transplant minimal residual disease‐positive acute myeloid leukemia patients with intermediate‐risk undergoing allogeneic stem cell transplantation in CR

C. Langebrake, F. Ayuk, C. Wolschke, 2022, European journal of haematology.

Enhanced Immune Reconstitution of γδ T Cells after Allogeneic Stem Cell Transplantation Overcomes the Negative Impact of Pretransplantation Minimal Residual Disease-Positive Status in Patients with Acute Myelogenous Leukemia

N. Kröger, F. Ayuk, C. Wolschke, 2021, Transplantation and Cellular Therapy.

CD34(+)-selected stem cell boost without further conditioning for poor graft function after allogeneic stem cell transplantation in patients with hematological malignancies.

N. Kröger, D. Blaise, C. Chabannon, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Challenges for Allogeneic Hematopoietic Stem Cell Transplantation in Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors

M. Baccarani, N. Kröger, A. Zander, 2011, Acta Haematologica.

Second-Generation Tyrosine Kinase Inhibitors in the Post-Transplant Period in Patients with Chronic Myeloid Leukemia or Philadelphia-Positive Acute Lymphoblastic Leukemia

N. Kröger, A. Zander, F. Ayuk, 2009, Acta Haematologica.

Molecular Diagnostics, Targeted Therapy, and the Indication for Allogeneic Stem Cell Transplantation in Acute Lymphoblastic Leukemia

T. Haferlach, N. Kröger, A. Zander, 2011, Advances in hematology.

Risk factors for outcome after allogeneic stem cell transplantation in patients with advanced phase CML

N. Kröger, I. Moiseev, B. Afanasyev, 2021, Bone Marrow Transplantation.

Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant.

P. Riedell, F. Awan, M. Krem, 2021, JAMA oncology.

Atovaquone for Prophylaxis of Toxoplasmosis after Allogeneic Hematopoietic Stem Cell Transplantation

H. Rohde, A. Bacher, N. Kröger, 2015, Acta Haematologica.

Effective prevention of GVHD using in vivo T-cell depletion with anti-lymphocyte globulin in HLA-identical or -mismatched sibling peripheral blood stem cell transplantation

N. Kröger, A. Zander, U. Pein, 2014, Bone Marrow Transplantation.

Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors.

Sonali M. Smith, M. Perales, R. Gale, 2016, Blood.

Long-Term Results of Prophylactic Donor Lymphocyte Infusions for Patients with Multiple Myeloma after Allogeneic Stem Cell Transplantation.

N. Kröger, A. Zander, C. Wolschke, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Second Allogeneic Stem Cell Transplantation in a Patient with Hypoplastic Myelodysplastic Syndrome following a Primary Diagnosis of Aplastic Anaemia

N. Kröger, A. Zander, F. Ayuk, 2010, Acta Haematologica.

TKI Maintenance After Stem-Cell Transplantation for FLT3-ITD Positive Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis

N. Kröger, C. Wolschke, N. Gagelmann, 2021, Frontiers in Immunology.

Evaluation of BM cytomorphology after allo-SCT in patients with AML

T. Haferlach, C. Bokemeyer, N. Kröger, 2012, Bone Marrow Transplantation.

Second allogeneic stem cell transplantation for relapse after allografting in multiple myeloma using CD 34+ selected donor cells without immunosuppression

N. Kröger, F. Ayuk, C. Wolschke, 2020, Bone Marrow Transplantation.

Enhanced immune reconstitution of γδ T cells after allograft overcomes negative impact of pre-transplant MRD positive status in AML patients.: γδ T cells and MRD+ AML.

N. Kröger, F. Ayuk, C. Wolschke, 2021, Transplantation and cellular therapy.

Daratumumab Is an Effective and Safe Salvage Therapy in Relapsed/Refractory Patients with Multiple Myeloma after Allogeneic Stem Cell Transplantation

N. Kröger, U. Pein, F. Ayuk, 2016 .